Market Overview

AiCuris, Merck Enter Exclusive Worldwide License Agreement


Merck (NYSE: MRK) and AiCuris today announced that they have entered into an exclusive
worldwide licensing agreement for AiCuris' novel portfolio of
investigational medicines targeting Human Cytomegalovirus (HCMV),
including letermovir (AIC246), an oral, late-stage antiviral candidate
being investigated for the treatment and prevention of HCMV infection in
transplant recipients.

"There is a significant need for additional medicines for the treatment
of HCMV infection, which is one of the most common viral infections
affecting organ and bone marrow transplant patients," said Dr. Roger
Pomerantz, senior vice president, Worldwide Licensing and Knowledge
Management, and Infectious Disease Franchise Head, Merck Research

See full press release

Posted-In: News Guidance Contracts Global


Related Articles (MRK)

View Comments and Join the Discussion!